- Fecal Incontinence
This enduring activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the management of inflammatory bowel disease.
Upon completion of this activity, participants should be better able to:
Describe the latest advances in basic/translational science in the management of IBD
Identify new evidence on the impact of therapeutic monitoring on short- and long-term outcomes
Discuss new data on potential adverse events of IBD therapy
Discuss the design and results of recent clinical trials in IBD for both established therapies and new therapies
Purdue University College of Pharmacy designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of Purdue University College of Pharmacy and the Gi Health Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Release Date: July 18, 2014
Expiration Date: July 18, 2015
*This program has expired. CME credit is no longer available.
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, Gi Health Foundation and Purdue University College of Pharmacy staff have no relationships to disclose.
Stephen Hanauer, MD
Stephen Hanauer, MD has disclosed that he received research support from AbbVie, Janssen Biotech, Inc. and Takeda Pharmaceuticals. Dr. Hanauer has also served as a consultant for AbbVie, Janssen Biotech, Inc., Salix Pharmaceuticals, Inc. and Takeda Pharmaceuticals.
Maria Abreu, MD
Maria Abreu, MD disclosed that she has served as a consultant for Prometheus Labs, Sanofi Aventis, Takeda, UCB, Pfizer, Janssen, Mucosal Healing Ad Board, WebMD Health, Prova Education, Inc., GSK Holding Americans, Inc. and Hospira, Inc. Dr. Abreu is an advisory board member for AbbVie Laboratories. Dr. Abreu also received honorarium from DDW, North America Round Table Ad Board, Florida Gastro Society, Synergy Medical Education/ Janssen Pharmaceuticals, IOIBD Scientific Program and the United European Gastroenterology.
Gary Lichtenstein, MD
Gary Lichtenstein, MD disclosed that he has served as a consultant for and has participated on the speaker’s bureau for Abbott, Elan, Meda Pharmaceuticals, Millennium Pharmaceuticals, Pfizer Pharmaceuticals, Santarus, Schering-Plough Corporation, Wyeth, Alaven, Janssen Biotech, Inc., Ferring, Procter & Gamble, Prometheus, Salix Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc., UCB, Inc., and Warner Chilcott. Dr. Lichtenstein has received grants and research support from Alaven, Bristol-Myers Squibb, Janssen Biotech, Inc., Ferring, Procter & Gamble, Prometheus, Salix Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc., UCB, Inc., and Warner Chilcott.
Amar Deshpande, MD
Amar Deshpande, MD, has nothing to disclose.